Beckers B, Brodersen H P, Stolpmann R M, Jansen G, Larbig D
Institut für Laboratoriumsmedizin, Mönchengladbach, Germany.
Infection. 1993 Jan-Feb;21(1):71-4. doi: 10.1007/BF01739321.
In order to establish guidelines for the dosage of teicoplanin, a new glycopeptide antibiotic, in patients with end stage renal failure, 40 cases of suspected or proven gram-positive infections were treated with teicoplanin. Three different dosage regimens were used and peak/trough serum levels measured. Thirty-one patients were cured and six patients died. Teicoplanin was well tolerated. For severe cases of septicemia with staphylococci in patients undergoing hemodialysis a teicoplanin therapy consisting of 800 mg on day 1 followed by administrations of 400 mg on days 2, 3, 5, 12, and 19 is recommended. Minor infections are treated initially with 800 mg followed by administration of 400 mg at weekly intervals.
为制定针对终末期肾衰竭患者的新型糖肽类抗生素替考拉宁的用药指南，对40例疑似或确诊革兰氏阳性菌感染患者使用替考拉宁进行治疗。采用了三种不同的给药方案，并测定了血清峰浓度/谷浓度。31例患者治愈，6例患者死亡。替考拉宁耐受性良好。对于接受血液透析的葡萄球菌败血症重症患者，建议采用替考拉宁治疗方案：第1天给予800mg，随后在第2、3、5、12和19天给予400mg。轻度感染最初给予800mg，随后每周间隔给予400mg。
